Yahoo / Market Guide - King Pharmaceuticals

Home - Yahoo! - Help

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Location

501 Fifth Street
Bristol, TN 37620

Phone: (423) 989-8000
Fax: (423) 274-8677
Email: investorrelations@kingpharm.com

Employees (last reported count): 1,642

Financial Links

·Top Institutional Holders
·Top Mutual Fund Holders
·Analyst Upgrade/Downgrade History
·Historical Quote Data
·Raw SEC Filings at sec.gov

Competitors:
·Sector: Healthcare
·Industry: Biotechnology & Drugs

Company Websites

·Home Page
·Yahoo! Category

·Search Yahoo! for related links...

Index Membership

·S&P 500

Ownership

·	Insider and 5%+ Owners: 24%
·	Over the last 6 months: · one insider buy; 0 shares · 9 insider sells; 1.79M shares (3.1% of insider shares)
·	Institutional: 80% (105% of float) (781 institutions)
·	Net Inst. Buying: 10.3M shares (+5.33%) (prior quarter to latest quarter)

More From Market Guide

·Highlights
·Performance
·Ratio Comparisons

Business Summary

King Pharmaceuticals, Inc. is a vertically integrated pharmaceutical company that manufactures, markets and sells primarily branded prescription pharmaceutical products. The Company markets its branded pharmaceutical products to general/family practitioners, internal medicine physicians, cardiologists, endocrinologists, pediatricians, obstetrician/gynecologists and hospitals. The Company markets a variety of branded prescription products primarily over four therapeutic areas: cardiovascular products, anti-infective products, critical care products and women's health products/endocrinology products. The Company's cardiovascular products include Altace, Thalitone and Procanbid. Anti-infective products include Lorabid, Bicillin, Cortisporin, Neosporin and Coly-Mycin. Critical care products include Thrombin-JMI and Brevital. The Company's women's health products/endocrinology products include Menest, Nordette, Levoxyl, Cytomel and Triostat.

More from Market Guide: Expanded Business Description

Financial Summary

King Pharmaceuticals is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells primarily branded prescription pharmaceutical products. For the six months ended 6/01, revenues rose 39% to $387.8 million. Net income before extraordinary item and acctg. change totalled $101.6 million, up from $40.9 million. Results reflect the acquisition and growth of branded pharmaceutical products and the absence of $22.3 million in merger and restructuring costs.

More from Market Guide: Significant Developments

Officers

[Insider Trade Data]

	FY2000 Pay

John Gregory, 48 Chairman, CEO	$370K
Jefferson Gregory, 45 Pres, Director	305K
Joseph Gregory, 47 Vice Chairman, Vice Chairman of Operations, Pres of Monarch Pharmaceuticals	309K
John Bellamy, 38 Exec. VP, Legal Affairs and Gen. Counsel	--
Kyle Macione, 37 Exec. VP, Corp. Affairs	168K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..

More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options

Statistics at a Glance -- NYSE:KG

As of 31-Aug-2001

Price and Volume
52-Week Low on 28-Sep-2000	$`20.443`
Recent Price	$`43.25`
52-Week High on 20-July-2001	$`46.05`
Beta	`0.41`
Daily Volume (3-month avg)	`1.52M`
Daily Volume (10-day avg)	`1.09M`
Stock Performance
big chart [1d \| 5d \| 3m \| 6m \| 1y \| 2y \| 5y]
52-Week Change	`+54.3%`
52-Week Change relative to S&P500	`+106.9%`
Share-Related Items
Market Capitalization	$`9.92B`
Shares Outstanding	`229.3M`
Float	`174.2M`
Dividends & Splits
Annual Dividend	none
Last Split: 4 for 3 on 20-July-2001

Per-Share Data
Book Value (mrq)	$`4.84`
Earnings (ttm)	$`0.70`
Earnings (mrq)	$`0.25`
Sales (ttm)	$`3.18`
Cash (mrq)	$`1.11`
Valuation Ratios
Price/Book (mrq)	`8.94`
Price/Earnings (ttm)	`61.44`
Price/Sales (ttm)	`13.61`
Income Statements
Sales (ttm)	$`729.4M`
EBITDA (ttm)	$`322.5M`
Income available to common (ttm)	$`165.2M`
Profitability
Profit Margin (ttm)	`22.7%`
Operating Margin (ttm)	`37.9%`
Fiscal Year
Fiscal Year Ends	Dec 31
Most recent quarter	30-June-2001

Management Effectiveness
Return on Assets (ttm)	`13.57%`
Return on Equity (ttm)	`18.82%`
Financial Strength
Current Ratio (mrq)	`3.66`
Debt/Equity (mrq)	`0.09`
Total Cash (mrq)	$`254.1M`
Short Interest As of 8-Aug-2001
Shares Short	`3.33M`
Percent of Float	`1.9%`
Shares Short (Prior Month)	`2.83M`
Short Ratio	`1.85`
Daily Volume	`1.80M`

See Profile Help for a description of each item above; M = millions; B = billions; mrq = most-recent quarter; ttm = trailing twelve months; (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.

Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.